Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017194789) INHIBITION OF BETA-2 NICOTINIC ACETYLCHOLINE RECEPTORS TO TREAT ALZHEIMER'S DISEASE PATHOLOGY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/194789 International Application No.: PCT/EP2017/061630
Publication Date: 16.11.2017 International Filing Date: 15.05.2017
IPC:
A61K 45/00 (2006.01) ,A61P 25/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants:
INSTITUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux 75015 PARIS, FR
Inventors:
MASKOS, Uwe; FR
LOMBARDO, Sylvia; US
CATTEAU, Julie; FR
BESSON, Morgane; FR
KOUKOULI, Fani; FR
Agent:
REGIMBEAU; 20, rue de Chazelles 75847 PARIS CEDEX 17, FR
Priority Data:
62/336,42813.05.2016US
Title (EN) INHIBITION OF BETA-2 NICOTINIC ACETYLCHOLINE RECEPTORS TO TREAT ALZHEIMER'S DISEASE PATHOLOGY
(FR) INHIBITION DE RÉCEPTEURS NICOTINIQUE BÊTA-2 DE L'ACÉTYLCHOLINE POUR TRAITER UNE PATHOLOGIE DE LA MALADIE D'ALZHEIMER
Abstract:
(EN) The invention provides methods of reducing development of mild cognitive impairment and/or learning disorders and/or memory disorders in a subject suspected to have or suffering from Alzheimer's disease (AD). In some embodiments,the methods comprise administering a therapeutically effective amount of a beta-2 nicotinic acetylcholine receptor (n AChR) antagonist and/or beta-2 nAChRnegative allosteric modulator (NAM) to the subject over a therapeutic dosing period to thereby reduce the rate of development of mild cognitive impairment and/or learning disorders and/or memory disorders in the subject over the therapeutic dosing period.
(FR) La présente invention concerne des procédés de réduction du développement de troubles cognitifs légers et/ou troubles de l'apprentissage et/ou troubles de la mémoire chez un sujet suspecté de souffrir ou souffrant de la maladie d'Alzheimer (MA). Dans certains modes de réalisation, les procédés comprennent l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur nicotinique bêta-2 de l'acétylcholine (nAChR) et/ou un modulateur allostérique négatif de nAChR bêta-2 (NAM) au sujet sur une période de dosage thérapeutique de façon à diminuer le taux de développement d'un trouble cognitif léger et/ou de troubles de l'apprentissage et/ou de troubles de la mémoire chez le sujet pendant la période de dosage thérapeutique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)